Clinical Study

S1801- A Phase II Randomized Study Of Adjuvant Versus Neoadjuvant Mk-3475 (Pembrolizumab) For Clinically Detectable Stage III-Iv High Risk Melanoma

Posted Date: Oct 1, 2019

  • Investigator: Rekha Chaudhary
  • Specialties: Cancer, Oncology, Skin Cancer
  • Type of Study: Drug

The goal of this study is To compare event-free survival (EFS) in patients with high-risk resectable melanoma randomized to neoadjuvant MK-3475 (pembrolizumab) with patients randomized to adjuvant MK-3475 (pembrolizumab)

Criteria:

To Be Eligible: Must Have Resectable Melanoma, >18 Years Of Age, No Other Active Infection Or Autoimmune Disease Needing Systemic Therapy, Nonpregnant/Nonbreastfeeding

Keywords:

Melanoma, Skin Cancer

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.